of the 44 million 'creditor claims' a least 40 million is 'disputed' claims so this company only had 4 million in unpaid 'expenses' with 3 million in cash. in 2022. why even pay a dime to some fake 40 million 'DISPUTED' claims. ? it was easier and more expedient to just declare chapter 11 but was the plan to go bankrupt. and get sued and collect the 5 million insurance payout.
I see that Sanofi has just filed Financial Statements and Supplemental Schedules for the years ended Dec 31, 2022 AND 2023, for both the US and Puerto Rico Group Savings Plans. I guess they're getting ready for Q3, and the spinoff of their healthcare sector.
Here, recently, we saw Humanigen file an Objection to equity claims filed by a relatively small number of holders
But we also saw that management planned to confirm the court's position on our conformance to the bankruptcy rules. They also reserved the right to modify the Combined Plan, if required to do so.
I think the Plan HAS to be modified, for two reasons. One reason is because the court recognized developments (details of which appear to be redacted), that will bring sufficient value to have justified an amendment to the Asset Purchase Agreement, allowing for additional Milestone Events and higher payments. So there will be no reason to decline a distribution to existing equity holders. It is clear that favorable regulatory approval/authorization is required to enact Milestone payments.
The very number of shares in Humanigen's market is, itself, a share price catalyst. whether the share structure was disclosed in the redacted information, or not. I would hope that the judge was advised of our share structure, but regardless, that information will be public knowledge as soon as we get the regulatory news of approval, such as for the treatment/prevention of CMML cancer, or whether the news comes in terms of unfolding business developments/alignments.
News 
Market Data 
Discover 
